Coronavirus Update: More Approval, Trial Progress For Non-Vaccine Options
Plus, SK's Vaccine Positive In Early Trial
Executive Summary
Multiple non-vaccine options for COVID-19 continue to progress, with promising new clinical results for Sorrento's small molecule drug and a supplementary approval in Japan for Chugai's antibody combo. Meanwhile, China's CRDC has in-licensed technology for Ligand to apply to an oral antiviral it is developing. Meanwhile, SK Biosciences' novel nanoparticle vaccine is positive in early trials.
You may also be interested in...
Korea Q3 Roundup: China Sales, Prescription Drugs, Vaccines Boost Results
Notable third-quarter developments at major Korean pharma firms included the domestic reimbursement of Yuhan’s Leclaza, the approval of Hanmi’s Rolontis and SK Bioscience's approval filing for Novavax's COVID-19 vaccine for supply in the country, a roundup of results by Scrip shows.
Chinese Biotech Bets On Intravenous 3CL Antiviral Contender For COVID-19
While new oral COVID-19 drugs are commanding the headlines, a little-known Chinese biotech is pushing ahead with an intravenous small molecule antiviral candidate now moving towards Phase II/III US trials, its CEO tells Scrip.
Hopes Rise For SK’s COVID-19 Vaccine As It Moves To Comparative Phase III Trial
Following positive interim Phase I/II results, expectations are rising for SK Bioscience’s recombinant COVID-19 vaccine as it becomes the first Korea-developed candidate to progress to Phase III.